Announcement • May 25
Cannabix Technologies Inc., Annual General Meeting, Jul 27, 2026 Cannabix Technologies Inc., Annual General Meeting, Jul 27, 2026. New Risk • Apr 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (CA$159k revenue, or US$114k). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$80.9m market cap, or US$58.3m). Announcement • Mar 17
Cannabix Technologies Inc Announces Commercial Launch of Marijuana Breath Test Cannabix Technologies Inc. announced the commencement of its commercial phased rollout of the Marijuana Breath Test system. This phase includes the delivery of Marijuana Breath Test units to select commercial customers across multiple industries, followed by a planned scale-up in production. The Marijuana Breath Test fills a critical gap and delivers new technology and methods that provide a complete, non-invasive solution for detecting recent cannabis use, specifically delta-9 THC in breath, within approximately 4 hours of consumption at levels above 5 pg/L. This capability addresses a long-standing need among employers, law enforcement agencies, and safety-sensitive industries, which have historically relied on testing methods that detect primarily past cannabis use. Accurate detection of recent use via breath is becoming essential for maintaining fairness, relevance, and informed decision-making. In early March 2026, an independent peer-reviewed publication in the Journal of Analytical Toxicology became publicly available confirming the ability of the Marijuana Breath Test system to detect delta-9 THC. Over recent months, Cannabix and its partners have completed many initiatives to enable the commercial rollout of the Marijuana Breath Test system: Key enhancements to the Breath Collection Unit and Breath Cartridges, along with the initial validation package prepared by Omega Laboratories. Integration of Cannabix Breath Cartridges into Omega’s operational workflows, including chain-of-custody processes and electronic reporting through its Laboratory Information Management System. Established manufacturing procedures and partnerships, standard operating procedures, and QA/QC processes for Marijuana Breath Test hardware. Breath Collection Unit successfully passing FCC electronic emissions testing. The Marijuana Breath Test system will follow a recurring revenue model in which the handheld Breath Collection Unit serves as the required hardware for all deployments, while disposable Breath Cartridges generate ongoing revenue as they are used for every test performed. Pre-launch marketing initiatives conducted with Omega and AlcoPro. Preparation of end-user training materials, logistics planning, and customer support resources. Release of peer-reviewed Journal of Analytical Toxicology publication, titled: “Simultaneous Analysis of ?9-THC, ?8-THC, CBD, and CBN in Breath Aerosols Collected Using Cannabix Technologies Breath Collection Unit.” The Marijuana Breath Test platform consists of the Cannabix Breath Collection Unit, disposable Breath Cartridges, and the Laboratory-Developed Test Method by Omega Laboratories. Cannabix has a strategic partnership with Omega Laboratories Inc, a global leader in forensic drug testing for over 25 years. Omega holds multiple federal and international certifications and operates a facility with extensive experience in novel drug detection technologies. Traditional cannabis testing methods such as urine, saliva, or hair analysis, primarily detect historical cannabis use. These methods can return positive results hours, days, or even weeks after consumption, making them ineffective for determining whether an individual may be using during the workday. Scientific research shows that delta-9 THC is detectable in breath for a short window of approximately 2–4 hours, closely aligned with the period of peak impairment. Breath analysis therefore provides the most relevant and scientifically meaningful indication of recent use, which is the metric employers and safety-sensitive industries require. 
